Terms and Conditions for the TIMIT Platform

Version 1.1 – effective from 18 August 2026 Classification: Public

I. Formation and Subscription

1. Introduction

Medibrix AS, with registered address at Sjøgata 5, 9405 Harstad, Norway, and organization number 912 540 863 ("Medibrix"), owns and operates TIMIT platform, an information and communication platform dedicated to the aesthetic treatment sector ("TIMIT platform"). The Customer gains access to the Platform on a subscription basis, in accordance with this Agreement.

TIMIT platform provides professional users (typically healthcare personnel) with access to the Platform through a common framework and user interface, developed and continuously evolved by Medibrix to facilitate efficient communication and information flow between professional users and end-users (patients/customers).

TIMIT platform is delivered as "Software as a Service" (SaaS) based on the Microsoft Azure platform and services. This means that TIMIT platform is web-based and operated and maintained by Medibrix.

2. Registration and Acceptance of Terms

The Customer registers for TIMIT platform by logging in via BankID and completing the registration process on the Website, providing the Customer's company name, organisation number, and contact e-mail address. Upon registration, the Customer confirms acceptance of this Agreement, including the Data Processing Agreement referred to and made available as a separate document, and the Price List, by clicking "I accept the terms of use of TIMIT platform and subscribe now" ("Acceptance").

By Acceptance, the Customer confirms that: (a) the person completing the registration has the authority to bind the Customer; (b) the information provided is correct; and (c) the Customer had the opportunity to review the Agreement, the Data Processing Agreement, and the Price List applicable at the time of registration.

Where the Customer continues as a paying Subscription, whether by clicking "Start subscription" or upon expiry of the Trial Period, the Customer shall additionally provide billing address, billing e-mail address (if different), and any invoice reference. This is a registration of additional information and does not require a new Acceptance.

The Agreement, including the Data Processing Agreement, comes into effect upon Acceptance - including for any Customer data the Customer registers in TIMIT platform during the Trial Period. No physical or digital signature is required, and no countersignature or confirmation from Medibrix is required for the Agreement to be binding.

The Customer and Medibrix are individually referred to as "Party" and collectively as "Parties".

3. TIMIT Platform and Services

Access to TIMIT platform is provided via the Website and can be accessed through a web browser. TIMIT is web-based and requires no installations at the Customer's end other than updated browsers of the types approved by Medibrix.

The Subscription gives the Customer's professional users access to the TIMIT platform's functionality for booking, treatment documentation, communication with end-users, and related administrative tools.

The Customer may activate digital forms ("Forms") as an additional service, enabling the Customer's professional users to collect structured information from end-users in connection with bookings or treatment. Forms are activated by the Customer in TIMIT platform and are invoiced in accordance with Invoicing.

Support for the Customer's professional users is included in the Subscription; support for end-users is not included.

The Subscription Fee applicable to the Customer's number of professional users is set out in the Price List published the Website, as updated from time to time in accordance with this Agreement.

4. Trial Period

Upon Acceptance, the Customer is granted a fourteen (14)-day trial period, during which the Customer has free access to TIMIT platform ("Trial Period"). The Trial Period commences on the date of Acceptance. The remaining Trial Period is shown to the Customer at all times in the TIMIT platform dashboard.

If the Customer cancels before expiry of the Trial Period, access to TIMIT platform terminates at the end of the Trial Period, and no Subscription Fee is charged. Cancellation during the Trial Period does not require any notice period.

If the Customer does not cancel before expiry of the Trial Period, the Subscription automatically continues as a paid Subscription, and the Customer will be invoiced from the first day following expiry of the Trial Period.

If the Customer has registered Customer data in TIMIT platform during the Trial Period and does not continue as a paying Subscription upon its expiry, the process set out in the Parties' Obligations upon Termination applies as if the Subscription had been terminated, with the expiry of the Trial Period as the starting point for the notice and deletion timeline.

II. Pricing and Payment

5. Invoicing

The Subscription Fee is invoiced to the Customer monthly in advance, based on the number of active professional users at the start of the invoicing month and the applicable pricing tier set out in this Agreement. Transaction costs for communication and login services are invoiced monthly in arrears, based on actual usage in the preceding month.

If the number of paying professional users changes during a month so that the Customer moves to a different pricing tier, the change takes effect from the first day of the following invoicing month, and the Subscription Fee is adjusted accordingly from that date.

The fee for Active Forms is invoiced monthly in arrears, based on the number of Forms that were in active use during the preceding month, at the price set out in the Price List.

All amounts set out in this Agreement are exclusive of value added tax (VAT), which shall be added in accordance with Applicable Law. The Customer shall pay each invoice within thirty (30) days of receipt.

Upon termination of the Agreement, the Customer shall pay the Subscription Fee up to and including the effective date of termination; no refund is given for the remainder of a prepaid month.

6. Transaction Costs

Use of TIMIT platform entails transaction costs associated with communication and login, invoiced monthly in arrears.

Communication with end-users primarily takes place via SMS, but other communication methods (such as e-mail or push notifications) may also be used. Communication is billed regardless of which method is used.

The TIMIT platform includes standard notification functionality that generates communication, such as booking confirmations and cancellation/rebooking notices in connection with appointments. These notifications result in transactions incurring costs as described below.

The TIMIT platform uses a standard SMS setup provided by a third party, which has conditions related to SMS length and the use of special characters. A message text typically consists of predefined text along with text added by the professional user. If long message texts or special characters (e.g., symbols and emojis) are used, it may be necessary to send the message as multiple message segments. Each message segment is billed according to the Price List. For e-mail or push notifications, there are no restrictions on the number of characters, and each message is considered a single message segment.

The Customer must always use messages with login invitations, as the entry point to TIMIT platform for end-users. An end-user is defined as a patient or customer using Customers services.

Medibrix may update the Price List for transaction costs when Medibrix's own costs from third-party providers (e.g. SMS or BankID providers) change, with at least one (1) month's written notice to the Customer before the adjusted price takes effect. Notice is given to the Customer through the invoice preceding the effective date of the update, showing the Customer's applicable transaction costs under the updated Price List. Such invoice notice constitutes the written notice required.

7. Price Adjustment

The Subscription Fee is fixed for the first twelve (12) months from the date of Acceptace. After the expiry of this period, Medibrix may update the Price List, thereby adjusting the Subscription Fee, by giving the Customer at least one (1) month's written notice before the adjusted price takes effect. Notice is given to the Customer through the invoice preceding the effective date of the update, showing the Customer's applicable Subscription Fee under the updated Price List. Such invoice notice constitutes the written notice required.

If the Customer does not accept the adjusted Subscription Fee, the Customer may terminate the Subscription before the adjusted price takes effect.

8. Payment Default and Late Payment Interest

If the Customer fails to pay by the due date, Medibrix is entitled to interest on the overdue amount from the first day of delayed payment, in accordance with Applicable Law on payment of debts. If the overdue amount, plus late payment interest, is not paid within forty-five (45) calendar days after the due date of Medibrix's invoice, Medibrix may send the Customer written notice that the Agreement may be terminated in whole or in part due to the Customer's default, unless payment is made within thirty (30) calendar days after receiving the notice. Termination for payment default shall not occur if the Customer pays the overdue amount, plus late payment interest, before the deadline expires.

III. Use of the TIMIT Platform

9. Account Administration and Communication Channels

The Customer is provided with access to an admin console for managing access to the TIMIT platform.

The Customer is responsible for safeguarding the password and other credentials used to access the TIMIT platform. Usernames, passwords, or other credentials shall not be shared with third parties.

The Customer is responsible for any activity on the account and for any use of the Customer's username, password, or other credentials.

Medibrix may communicate with the Customer through TIMIT platform, via the Customer's registered contact e-mail address, or via other electronic channels communicated by Medibrix. All information and notifications communicated through such channels shall be considered known to the Customer; however, in the case of termination of the Agreement or notice of breach, Medibrix shall use e-mail.

10. Usage Rights and Limitations

The Customer is granted a non-exclusive, payable, non-sublicensable, non-transferable right to use TIMIT platform during the Subscription period, in accordance with this Agreement.

The Customer's use of TIMIT platform is limited to the Customer's ordinary business activities in the country where the Customer is established, and to the Customer's own use. This does not include commercializing as TIMIT platform.

The Customer shall not sublicense or transfer the rights granted under this Agreement, and gains no rights to any intellectual property held by Medibrix or its licensors beyond what is expressly stated herein. The Customer has no right to access executable code or source code for TIMIT platform, and only gains access to TIMIT platform as a software-as-a-service through designated interfaces.

The Customer shall not, and shall not allow others to:

a) modify, adapt, translate, reverse engineer, decompile, or disassemble TIMIT platform, or attempt to discover its source code, underlying ideas, algorithms, or file formats; or

b) create derivative works of, reproduce, distribute, sell, or resell TIMIT platform or other Medibrix technology; or

c) use information received from Medibrix regarding TIMIT platform to develop, integrate, market, license, distribute, or host a competing product or service.

11. Functionality and Availability (SLA)

TIMIT platform is available for use 24/7 throughout the year. However, Medibrix cannot guarantee continuous availability and reserves the right to perform necessary maintenance and upgrades, as well as temporarily take down the platform if required. Planned changes/upgrades and maintenance will be notified via the Website and/or via email to the Customer's contact person in case of significant changes. The Customer cannot object to service interruptions as a result of planned upgrades.

12. Acceptable Use

The Customer is responsible for its use of TIMIT platform, its Customer Data, and its communication with others through the platform. The Customer shall: (a) use TIMIT platform only in accordance with Applicable Law; (b) not disrupt normal use of TIMIT platform or attempt to access it other than through the designated interfaces; (c) not circumvent or attempt to circumvent any limitations Medibrix applies to the Customer's account; (d) not investigate, scan, or test the vulnerability of TIMIT platform or systems used to deliver it, without Medibrix´s prior written consent; and (e) not contribute to undue or excessive use of TIMIT platform that negatively affects its speed, response, stability, availability, or functionality for other users. Medibrix will endeavor to notify the Customer of such use before taking further action.

13. Customer Responsibility for Treatment and Regulatory Compliance

Medibrix is not responsible for the Customer's use of TIMIT platform, the Customer's underlying services delivered to end-users, or the Customer's marketing of such services. The Customer is fully responsible for these matters.

Medibrix does not verify that the Customer's professional users hold the professional qualifications, authorizations, or approvals required under Applicable Law to perform the treatments they offer through TIMIT platform, including any required prior approval of a treatment by another qualified person. The Customer is solely responsible for ensuring that its professional users are duly qualified and authorized, and that all regulatory approvals required for a given treatment have been obtained before the treatment is performed or documented in TIMIT platform.

14. Open Source and Third-Party License Term

The TIMIT platform may be based on open source or third-party licensed software. Relevant open-source licenses and other third-party licenses are published in the TIMIT platform. The Customer shall comply with the terms of any applicable third-party licenses.

15. Changes to the Platform and SLA

Medibrix has the right to make commercially reasonable changes to the TIMIT platform and SLA from time to time. TIMIT platform is developed dynamically, and new features will always be available to the Customer as part of the Subscription. New services may also be developed; these are not included in the Subscription but can be activated as additional services under the Subscription.

Medibrix shall provide written notice if Medibrix intends to (a) terminate or (b) make backward incompatible changes to the functionality of TIMIT platform. Such changes will be notified through TIMIT platform.

Medibrix shall reasonably endeavor to continue the functionality of TIMIT platform without such changes for at least three (3) months after the notice, unless: (a) the change is required due to Applicable Law and cannot be postponed without violating the law; (b) continued operation of the TIMIT platform poses a security risk; or (c) Customer-specific features are replaced by functionally equivalent standard features.

16. Changes to Agreement Terms

Medibrix reserves the right to unilaterally adopt changes to this Agreement. Significant changes unfavorable to the Customer and not resulting from Applicable Law require the Customer's acceptance through a renewed click-to-accept upon the Customer's next login, and take effect from the date of such acceptance.

If the Customer does not accept such a change within thirty (30) days of Medibrix's notice, or considers the change to be a significant change unfavorable to the Customer, the Customer may terminate the Subscription in accordance with this Agreement before the change takes effect.

If the Customer neither accepts nor terminates the Subscription within the notice period referred to above, the Customer's continued use of TIMIT platform after expiry of that period constitutes acceptance of the change. Medibrix may, in addition, require the Customer to actively accept or decline the change upon next login before further use of TIMIT platform.

Other changes to this Agreement are communicated through TIMIT platform and take effect as stated in the notice.

IV. Liability and Risk

17. Delivery Responsibility

Medibrix shall deliver TIMIT platform in accordance with generally accepted professional standards. The Customer accepts that the TIMIT platform may have errors, and unless otherwise agreed in a writing, TIMIT platform and associated services are provided "as is." Medibrix does not warrant that the TIMIT platform is error-free.

Medibrix notes that telecommunications operators assume that approx. 0.5% of SMS may never reach their destination. Medibrix is not responsible for this or other errors in the telecommunication services of its subcontractors.

If the TIMIT platform is not delivered in accordance with the above, and Medibrix does not remedy the breach, the Customer may terminate the Agreement in accordance with Termination for Cause, but only if the breach is material.

18. IPR

Medibrix, or the relevant third-party licensor, is and shall remain the owner of TIMIT platform and all technology used to make it available to the Customer.

Each Party is and remains the owner of its own Background IPR, and this Agreement does not affect such ownership. No rights to the other Party's Background IPR are acquired under the Agreement unless expressly agreed in writing.

Medibrix, or the relevant third-party licensor, shall be and remain the sole owner of all Improvements and all IPR related to TIMIT platform, regardless of any contributions from the Customer. Medibrix has the right to use and commercialize any Improvements at its discretion and without any restrictions.

19. Customer Data

Unless otherwise agreed, the Customer retains ownership of Customer Data. Except as stated in this Section, Medibrix shall not use Customer Data for any purpose other than fulfilling Medibrix's obligations to the Customer and/or Applicable Law.

Medibrix is responsible for an ongoing assessment of information security and shall treat all information in accordance with Applicable Law, including applicable requirements for information security in connection with the processing of health data.

To allow Medibrix to continue developing the TIMIT platform, the Customer grants Medibrix a gratuitous, royalty-free, sublicensable license to use anonymized Customer Data during the Subscription period for product development purposes, including training algorithms on anonymized Customer Data.

Medibrix is the data processor for all patient and personal information registered by the Customer in TIMIT platform. The Data Processing Agreement applies to such processing.

Medibrix' privacy notice is available on the Website and describes Medibrix's processing of personal information as data processor on behalf of the Customer who is the data controller. The Customer is responsible for reviewing the privacy notice and informing Medibrix if it needs to be expanded or changed as a result of the Customer's processing of personal information.

20. IPR Indemnification

Medibrix shall indemnify the Customer against any third-party claim that the Customer's use of the TIMIT platform in accordance with this Agreement infringes such third-party Intellectual Property Rights (IPR), provided that Medibrix is promptly given full control over the defense of the claim and the Customer does not prejudice that defense. The Customer shall reasonably assist Medibrix in handling the claim. Indemnification does not apply if the claim arises from the Customer's use of TIMIT platform other than in accordance with this Agreement.

To avoid or remedy an infringement, Medibrix may, at its discretion, replace or modify TIMIT platform, provide an equivalent non-infringing solution, or make TIMIT platform unavailable to the Customer, including by suspending the Customer's access.

If Medibrix does not resolve the infringement or provide an equally effective solution within a reasonable time, the Customer may terminate the Agreement in accordance with Termination for Cause and claim compensation within the limits of Limitation of Liability. Beyond this, Medibrix has no liability to the Customer for infringement of third-party IPR.

21. Handling of Indemnified Claims

A Party shall promptly notify the other Party of any claim covered by the other Party's duty to indemnify. Where possible, the indemnifying Party shall take over the defense of the claim, and the Parties shall provide each other with the information and assistance reasonably necessary. The indemnified Party shall not settle or otherwise dispose of the claim without the indemnifying Party's written consent.

22. Limitation of Liability

Neither Party is liable to the other for indirect loss or consequential loss, including but not limited to loss of production, revenue, income, expected cost savings, loss or destruction of Customer Data, third-party claims, or loss of profit.

Each Party's total liability arising from or in connection with this Agreement shall not exceed an amount equal to twelve (12) months' Subscription Fee paid by the Customer, excluding transaction costs and VAT. This cap is cumulative per 12-month period, not per event.

The limitations in this Section do not apply to (a) the Customer's payment obligations, (b) a Party's indemnification obligations under this Section or under Parties' Obligations upon Termination, or (c) loss caused by gross negligence or willful misconduct.

23. Confidentiality

Each Party shall keep confidential all information received from the other Party that is marked as confidential or that, by its nature, should reasonably be understood to be confidential ("Confidential Information"), and shall not disclose it to third parties or use it for any purpose other than to fulfil this Agreement.

The confidentiality obligation does not apply to information that: (a) was already lawfully known by the receiving Party without a confidentiality obligation; (b) is or becomes publicly available other than through breach of this Section; (c) is received from a third party without breach of any confidentiality obligation; or (d) must be disclosed pursuant to Applicable Law, in which case only the portion required shall be disclosed.

Medibrix may disclose Confidential Information to subcontractors and third parties to the extent necessary to fulfil this Agreement, provided such third party is bound by confidentiality obligation at least as strict as those in this Section.

Each Party shall ensure that Confidential Information is handled securely, including that electronically stored information is inaccessible to unauthorized individuals.

The confidentiality obligation survives termination of this Agreement for ten (10) years, and indefinitely for Confidential Information constituting personal data or trade secrets.

24. Compliance with Applicable Law

Each Party shall comply with Applicable Law and any decisions from competent authorities, both generally and in connection with this Agreement.

Each Party shall ensure that taxes and fees are paid in accordance with Applicable Law and shall not, directly or indirectly, for its own part or on behalf of others: (a) provide, offer, request, or accept any undue advantage in connection with the performance of an office, position, or assignment; or (b) provide, offer, request, or accept any undue advantage with the purpose of influencing such performance.

V. Termination

25. Subscription Period and Termination

Following expiry of the Trial Period, the Subscription continues automatically as a paid Subscription for an indefinite period, with no minimum term.

The Customer may terminate the Subscription at any time, with three (3) months' notice, either through the cancellation function in TIMIT platform or by written notice to Medibrix sent by e-mail to contact@medibrix.com. Medibrix may terminate the Subscription by written notice to the Customer on the same notice period.

The notice period runs from the end of the calendar month in which notice is given, and the Subscription terminates at the end of the third subsequent calendar month, consistent with the monthly invoicing of the Subscription Fee.

The Customer remains liable for the Subscription Fee and any transaction costs incurred up to and including the last calendar month of the Subscription. No part of a prepaid calendar month is refunded. Upon termination, the deletion and export process set out in Parties' Obligations upon Termination applies.

26. Termination for Cause

Either Party may terminate the Agreement by written notice if the other Party materially breaches the Agreement and fails to remedy the breach within thirty (30) calendar days after written notice describing the breach and stating that termination may follow.

The following shall always be deemed a material breach by the Customer, without limiting what else may constitute a material breach: (a) a failure to pay any due and undisputed amount within thirty (30) calendar days after written notice that payment is overdue, in accordance with Payment Default and Late Payment Interest; (b) breach of the Acceptable Use provisions of this Agreement; (c) the Customer shares, or through gross negligence allows unauthorized third parties to obtain, BankID credentials, login details, or platform access; (d) breach of the Data Processing Agreement; or (e) providing materially false information at registration or Acceptance.

A breach by Medibrix is material if it substantially deprives the Customer of the benefit the Customer was entitled to expect under the Agreement, such as an uncured failure to deliver TIMIT platform in accordance with Delivery Responsibility.

If a material breach by the Customer cannot be remedied, Medibrix may terminate with immediate effect. Either Party may also terminate with immediate effect if debt negotiations, composition, bankruptcy, or other creditor control proceedings are initiated against the other Party, provided this is not contrary to mandatory law.

Termination is ex nunc; no amounts already paid are refunded, except that if the Customer rightfully terminates due to Medibrix's uncured material breach, Medibrix shall refund the prepaid Subscription Fee on a pro rata basis for the remaining full calendar days of the invoiced month. This refund is the Customer's sole remedy for the breach giving rise to termination, without prejudice to Limitation of Liability; no refund is made for transaction costs, set-up fees, or other one-time charges.

If Medibrix terminates due to the Customer's uncured material breach, no refund is made, and the Customer remains liable for the Subscription Fee for the notice period that would otherwise have applied under Subscription Period and Termination.

27. Parties' Obligations upon Termination

Upon termination of the Subscription - including where the Customer does not continue as a paying Subscription upon expiry of the Trial Period after having registered Customer data in TIMIT platform - Medibrix will notify the Customer that Customer Data will be deleted from TIMIT platform.

The Customer is solely responsible for ensuring that any statutory retention requirements applicable to the Customer's business - including, but not limited to, requirements under the Applicable Law regarding retention of patient journal records, including data relating to approval of treatment - are complied with before Customer Data is deleted.

Before deletion, the Customer may, in TIMIT platform: (a) export the Customer Data the Customer is required to retain; or (b) confirm that the relevant patient data is already documented in the Customer's primary patient journal system outside TIMIT platform, and that export is therefore not required.

Medibrix will notify the Customer of the upcoming deletion at least 30 days in advance through TIMIT platform and/or by e-mail to the Customer's registered contact address. If the Customer takes no action in accordance with (a) or (b) above before the notified deletion date, Customer Data is deleted automatically.

Medibrix reserves the right to delete Customer Data at any time after the notice period referred to above has expired, but is not obliged to delete Customer Data on a specific date.

Medibrix has no obligation to retain, export, or otherwise preserve Customer Data after deletion in accordance with this Section. Medibrix's deletion of Customer Data does not relieve the Customer of any statutory obligation to retain such data, and the Customer shall hold Medibrix harmless from any claim arising from the Customer's failure to export or retain data as required by applicable law.

VI. Final Provisions

28. Governing Law and Dispute Resolution

This Agreement is governed by the laws of Norway, without regard to its conflict of law principles.

Any dispute arising out of or in connection with this Agreement shall be attempted resolved through negotiations between the Parties. If not resolved within thirty (30) days, either Party may bring the dispute before the ordinary courts, with Oslo District Court as agreed venue.

29. Assignment and Subcontractors

Neither Party may transfer this Agreement without the other Party's written consent, which shall not be unreasonably withheld or delayed. Medibrix may transfer this Agreement to any company that directly or indirectly controls, is controlled by, or is under common control with Medibrix, without the Customer's consent.

Medibrix has the right to use subcontractors and is responsible for their performance as for its own.

30. Reference Rights

Medibrix may refer to the Customer as a user of TIMIT platform in its marketing, including using the Customer's company name and logo for this purpose, unless the Customer objects in writing.

31. Force Majeure

If an extraordinary situation beyond a Party's control makes it impossible to fulfil its obligations under this Agreement — including war, strike, lockout, riot, epidemic, pandemic, or natural disaster — the affected Party shall notify the other Party as soon as reasonably possible, and its obligations are suspended for the duration of the event. The Customer cannot invoke force majeure as a basis for not paying amounts due, except where the force majeure affects payment systems.

Each Party shall keep the other Party informed of the actual and potential effects of the event, steps taken to mitigate it, and its expected duration.

Either Party may terminate the Agreement if the force majeure event lasts, or is expected to last, more than ninety (90) calendar days, with fifteen (15) calendar days' written notice. Each Party bears its own costs of such termination, and neither Party may claim compensation from the other as a result.

32. Integration Clause

The Agreement, together with the Data Processing Agreement, constitutes the entire agreement between Medibrix and the Customer regarding the Subscription, and supersedes any prior or contemporaneous agreements or understandings, written or oral, on the same subject. Although the Data Processing Agreement is made available as a separate document, it forms an integral and binding part of this Agreement.

VII. Definitions

"Acceptance" means the Customer's electronic acceptance of this Agreement and the Data Processing Agreement, given by logging in via BankID and clicking the button confirming acceptance of the terms of use of TIMIT and subscription to the Subscription.

"Active Form" means a Form that has been used at least once by the Customer's professional users during a given calendar month.

"Agreement" means these Terms and Conditions together with the Data Processing Agreement and the Price List referred to herein.

"Applicable Law" means all current laws, regulations, requirements, or ordinances issued by a public authority with legal authority to exercise legislative, judicial, regulatory, or administrative functions.

"Background IPR" means any IPR that a Party has created or otherwise acquired prior to or independently of the Agreement.

"Confidential Information" means all information exchanged between the Parties that can reasonably be considered proprietary or confidential, whether marked as such or not, including but not limited to procedures, documentation, technical data, software, source code, and pricing information.

"Customer" means the legal entity that completes registration and gives Acceptance, as identified by the company name and organisation number provided during registration.

"Customer Data" means all data provided to or registered in TIMIT platform by or on behalf of the Customer, including personal data and health data.

"Data Controller" and "Data Processor" have the meaning set out in Applicable Law on the protection of personal data.

"Data Processing Agreement" means the agreement between Medibrix, as data processor, and the Customer, as data controller, governing Medibrix's processing of personal and health data on behalf of the Customer in connection with the Subscription. The Data Processing Agreement is made available as a separate document and forms an integral and binding part of the Agreement, entered into together with, and on the same terms as, the Customer's Acceptance.

"End User" means a patient or customer receiving treatment services from the Customer's professional users.

"Improvements" means any modifications, enhancements, or further development of TIMIT platform or other services provided under this Agreement.

"IPR" means intellectual property rights of any kind that exist now or in the future anywhere in the world, whether registered or not, and all applications, renewals, and extensions thereof, including but not limited to patents, trademarks, design rights, copyright, database rights, logos, business names, domain names, goodwill, know-how, trade secrets, and other protected material in any form, including rights in inventions, technology, data, algorithms, and computer programs.

"Price List" means the price list for the Subscription Fee and transaction costs, published ont the Website, as updated by Medibrix from time to time.

"Professional User" means an individual authorized by the Customer to use TIMIT platform to deliver or document treatment services to End Users.

"SLA" means Medibrix's service level commitment regarding the availability of TIMIT platform.

"Subscription" means the right to access and use TIMIT platform in accordance with this Agreement.

"Subscription Fee" means the recurring monthly fee for the Subscription, as set out in the Price List.

"Trial Period" means the fourteen (14) day period of free access to TIMIT platform granted to the Customer immediately following Acceptance, during which no Subscription Fee is charged and no notice period applies for cancellation.

"Website" means the domain through which the Customer accesses TIMIT platform and related information, currently https://timit.com, as updated by Medibrix from time to time.